Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

被引:264
作者
Pongers-Willemse, MJ
Verhagen, OJHM
Tibbe, GJM
Wijkhuijs, AJM
de Haas, V
Roovers, E
van der Schoot, CE
van Dongen, JJM
机构
[1] Erasmus Univ, Univ Rotterdam Hosp, Dept Immunol, NL-3000 DR Rotterdam, Netherlands
[2] Netherlands Blood Transfus Serv, Cent Lab, Dept Immunohematol, Amsterdam, Netherlands
[3] PE Biosyst, Nieuwerkerk Aan Den Ijss, Netherlands
关键词
RQ-PCR; quantification; MRD; immunoglobulin genes; T cell receptor genes; junctional region; ALL;
D O I
10.1038/sj.leu.2401246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Analysis of minimal residual disease (MRD) can predict outcome in acute lymphoblastic leukemia (ALL). A large prospective study in childhood ALL has shown that MRD analysis using immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements as PCR targets can identify good and poor prognosis groups of substantial size that might profit from treatment adaptation. This MRD-based risk group assignment was based on the kinetics of tumor reduction. Consequently, the level of MRD has to be defined precisely in follow-up samples. However, current PCR methods do not allow easy and accurate quantification. We have tested 'real-time' quantitative PCR (RQ-PCR) using the TaqMan technology and compared its sensitivity with two conventional MRD-PCR methods, ie dot-blot and liquid hybridization of PCR amplified Ig/TCR gene rearrangements using clone-specific radioactive probes. In RQ-PCR the generated specific PCR product is measured at each cycle ('real-time') by cleavage of a fluorogenic intrinsic TaqMan probe. The junctional regions of rearranged Ig/TCR genes define the specificity and sensitivity of PCR-based MRD detection in ALL and are generally used to design a patient-specific probe. In the TaqMan technology we have chosen for the same approach with the design of patient-specific TaqMan probes at the position of the junctional regions. We developed primers/probe combinations for RQ-PCR analysis of a total of three IGH, two TCRD, two TCRG and three IGK gene rearrangements in four randomly chosen precursor-B-ALL. In one patient, 12 bone marrow follow-up samples were analyzed for the presence of MRD using an IGK PCR target. The sensitivity of the RQ-PCR technique appeared to be comparable to the dot-blot method, but less sensitive than liquid hybridization. Although it still is a relatively expensive method, RQ-PCR allows sensitive, reproducible and quantitative MRD detection with a high throughput of samples providing possibilities for semi-automation. We consider this novel technique as an important step forward towards routinely performed diagnostic MRD studies.
引用
收藏
页码:2006 / 2014
页数:9
相关论文
共 46 条
[1]   DETECTION OF MINIMAL RESIDUAL LEUKEMIA BY THE POLYMERASE CHAIN-REACTION - POTENTIAL IMPLICATIONS FOR THERAPY [J].
BARTRAM, CR .
CLINICA CHIMICA ACTA, 1993, 217 (01) :75-83
[2]   ANALYSIS OF IG AND T-CELL RECEPTOR GENES IN 40 CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AT DIAGNOSIS AND SUBSEQUENT RELAPSE - IMPLICATIONS FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE BY POLYMERASE CHAIN-REACTION ANALYSIS [J].
BEISHUIZEN, A ;
VERHOEVEN, MAJ ;
VANWERING, ER ;
HAHLEN, K ;
HOOIJKAAS, H ;
VANDONGEN, JJM .
BLOOD, 1994, 83 (08) :2238-2247
[3]  
BEISHUIZEN A, 1993, LEUKEMIA, V7, P2045
[4]  
BEISHUIZEN A, 1991, LEUKEMIA, V5, P657
[5]  
BEISHUIZEN A, 1994, LEUKEMIA, V8, P2228
[6]   Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias:: a new molecular target for detection of minimal residual disease [J].
Beishuizen, A ;
de Bruijn, MAC ;
Pongers-Willemse, MJ ;
Verhoeven, MAJ ;
van Wering, ER ;
Hählen, K ;
Breit, TM ;
de Bruin-Versteeg, S ;
Hooijkaas, H ;
van Dongen, JJM .
LEUKEMIA, 1997, 11 (12) :2200-2207
[7]  
BREIT TM, 1993, BLOOD, V82, P3063
[8]   OUTCOME PREDICTION IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA BY MOLECULAR QUANTIFICATION OF RESIDUAL DISEASE AT THE END OF INDUCTION [J].
BRISCO, MJ ;
CONDON, J ;
HUGHES, E ;
NEOH, SH ;
SYKES, PJ ;
SESHADRI, R ;
TOOGOOD, I ;
WATERS, K ;
TAURO, G ;
EKERT, H ;
MORLEY, AA .
LANCET, 1994, 343 (8891) :196-200
[9]   DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA - METHODOLOGIC ADVANCES AND CLINICAL-SIGNIFICANCE [J].
CAMPANA, D ;
PUI, CH .
BLOOD, 1995, 85 (06) :1416-1434
[10]   Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia [J].
Cavé, H ;
ten Bosch, JV ;
Suciu, S ;
Guidal, C ;
Waterkeyn, C ;
Otten, J ;
Bakkus, M ;
Thielemans, K ;
Grandchamp, B ;
Vilmer, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :591-598